General MedicationsSUBCUTANEOUSStandard

LANREOTIDE ACETATE

Standard Dose

EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview LANREOTIDE ACETATE is listed in Drugs@FDA under application 217193 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LANREOTIDE ACETATE Form and strength SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) Sponsor INVAGEN PHARMS Submission history Latest submission status date: 2024-05-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview LANREOTIDE ACETATE is listed in Drugs@FDA under application 217193 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LANREOTIDE ACETATE Form and strength SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) Sponsor INVAGEN PHARMS Submission history Latest submission status date: 2024-05-21 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.